Navigation Links
S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
Date:5/4/2011

and has now completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, SB939, is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo Partners:Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251Associate Director, Corporate Development

Tony.Russo@russopartnersllc.com Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235yinchin_hew@sbio.com

Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
3. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care ... several new IT value-added reseller (VAR) national contracts ... with IT goods and services at lower costs. ... well as value-added services such as initiative assistance ... New Novation agreements were awarded to CDW Government, ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ... the practice of dermatology for clinical and aesthetic dermatology ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... N.J., Dec. 7, 2011 Updated results of ... plus exemestane, a hormonal therapy, show everolimus provided ... without their disease progressing (progression-free survival)(1). ... months of follow-up, were presented at the 2011 ...
... Dec. 7, 2011 Jia-Hwa Fang, Ph.D., has ... Manufacturing.  In this new role, he will lead ... Laboratory Practice (GLP), and pilot formulations for early ... Manufacturing Practices (GMP).  He will be responsible for ...
Cached Medicine Technology:New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 2New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 3New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 4New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 5New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 6New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 7New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 8New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 9New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 10Jia-Hwa Fang Joins SRI Biosciences as Director of Clinical Manufacturing 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and P4 have clear and distinct effects on inflammatory ... infection. Recently, Ohtani et al., have shown a protective ... Other studies have demonstrated that E2 and P4 have ... been reported in human, mouse and rat stomach. However, ...
... Allergy Testing in Improving Asthma ... ... Health announced today,that it has entered a co-promotion agreement with Phadia, ... in the diagnosis,and treatment of asthma and other respiratory diseases. Under ...
... Oct. 31 In the final 72-hours of,this ... volunteers,across the country are joining 4,000 SEIU members, ... the job to bring home victory for,Barack Obama, ... working,families need., SEIU,s major GOTV operations are ...
... an exaggerated intestinal immune response to otherwise innocuous ... plays a key role in the pathophysiology of ... yet emerged. Vitamin E is a major lipophilic ... which protects membrane lipids from peroxidation by scavenging ...
... to sign up online at http://www.diabetesatlanta.org , ATLANTA, ... than 600,000 Georgians, could be present in more than,300,000 more, ... disease?, No. The answer is diabetes., And, new ... the U.S. has,nearly doubled in the past 10 years - ...
... Array of Colors and,Custom Products Giving Confident Wearers ... PISCATAWAY, N.J., Oct. 31 Siemens Hearing,Instruments, Inc., ... States, continues their commitment to personalizing solutions for,those ... hearing instruments,were announced at this year,s International Congress ...
Cached Medicine News:Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 3Health News:Nation's #1 Respiratory Hospital Enters Agreement to Co-Promote IgE Blood Testing 2Health News:In Final 72-Hour Push, SEIU Members Get Out The Vote for Barack Obama and Other Working Family Candidates Across the Country 2Health News:Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis? 2Health News:As Diabetes Reaches Epidemic Levels in Georgia and U.S., Thousands Drawn to Diabetes University in Atlanta Nov. 8 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 3Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 4
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: